The gabapentin market is registering a valuation of USD 2.11 billion in 2023 and is estimated to reach USD 3.54 billion by 2033. The market is securing a CAGR of 5.3% during the forecast period.
The market has been growing rapidly due to several driving factors, including:
Increasing prevalence of neuropathic pain: As the global population ages, the prevalence of neuropathic pain is expected to increase. It has led to an increased demand for medications like gabapentin that can effectively treat this type of pain.
Growing off-label use: While gabapentin is only approved for certain medical conditions, it has been increasingly prescribed off-label for various conditions. It has led to a significant increase in demand for medication.
Increased awareness and availability: As more people become aware of gabapentin's effectiveness in treating certain conditions, demand for the medication has increased. Additionally, the medication has become more widely available, further contributing to its popularity.
Low cost: Gabapentin is a relatively inexpensive medication compared to other medications used to treat similar conditions. It has made it an attractive option for patients and healthcare providers alike.
Development of new formulations: In recent years, new formulations of gabapentin have been developed that offer improved efficacy and ease of use. It has further contributed to the growth of the gabapentin market.
| Attributes | Details |
|---|---|
| Market CAGR (2023 to 2033) | 5.3% |
| Market Valuation (2023) | USD 2.11 billion |
| Market Valuation (2033) | USD 3.54 billion |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Despite the growth drivers, several factors may restrain the market, including:
Side effects: Gabapentin can cause various side effects, including dizziness, drowsiness, and nausea. Sometimes, it can cause more serious side effects, such as suicidal thoughts or behaviors. These side effects can limit its use in certain patient populations and lead to decreased medication demand.
Misuse and abuse: While gabapentin has a low potential for abuse, it has been increasingly misused and abused, particularly in combination with opioids. It has led to concerns about its safety and potential for addiction, which may limit its use and demand.
Patent expiration: The patent for gabapentin has expired, which has led to the development of generic versions of the medication. It has increased competition in the market and led to a decrease in the price of the medication, which may limit its profitability for manufacturers.
Regulatory concerns: The off-label use of gabapentin has led to regulatory concerns, particularly in the United States. The medication has been classified as a controlled substance in certain states. It may limit its use and demand in these areas.
Availability of alternative treatments: There are alternative medications and treatments available for many conditions that gabapentin treats. These alternatives may be more effective or have fewer side effects, which may limit the demand for gabapentin.
According to the FMI report, the global market size was valued at USD 2.03 billion in 2020 with a CAGR of 4.6%. The increasing prevalence of neurological disorders, such as epilepsy and neuropathic pain, are the primary indications for gabapentin.
Regarding geographic segmentation, North America is expected to dominate the gabapentin market during the forecast period. It can be attributed to the high prevalence of neurological disorders and the presence of leading pharmaceutical companies in the region. Market trends and projections can change rapidly depending on various factors, including competition and technological advances.
Short Term (2023 to 2026): The rising neuropathic pain and disorders are increasing the demand for gabapentin in this time frame. People are more concerned about their health; therefore, for effective treatment, the adoption of gabapentin is rising.
Medium Term (2026 to 2029): The manufacturers are developing several therapies and medications for the patients to maintain their healthy life. These manufacturers are innovating low-cost products with effective advanced technologies to treat patients as per their requirements.
Long Term (2029 to 2033): Growing key players, research & development activities, and new formulations in the healthcare sector for patient recovery. The key companies are adopting several marketing tactics to uplift the market expansion in the coming period. The rising chronic diseases among old age patients around the globe are increasing the adoption of gabapentin.
Principal Consultant
Gabapentin is available in various dosage forms, including capsules, tablets, oral solutions, and extended-release formulations. However, is commonly prescribed form of gabapentin is oral capsules.
According to FMI, the capsule segment dominate the market, accounting for a significant share by 2033. It can be attributed to the ease of administration and accurate dosing provided by capsules and their widespread availability.
Tablets are also a popular dosage form for gabapentin, commonly prescribed for patients who have difficulty swallowing capsules. Oral solutions and extended-release formulations of gabapentin are relatively less common. They may be prescribed in certain cases, such as for patients with difficulty swallowing or requiring a more controlled release of the medication.
Gabapentin primarily treats epilepsy and neuropathic pain, including diabetic neuropathy, post-herpetic neuralgia, and trigeminal neuralgia. It is also used off-label for conditions such as anxiety disorders and insomnia.
In terms of type, the gabapentin market is segmented into branded and generic products. The generic segment dominates the market by capturing a significant share by 2033. The availability of several generic drug versions at lower prices leads to increased treatment options.
The market in the United States is significant, with the drug being one of the most widely prescribed medications in the country. Gabapentin is primarily used to treat epilepsy and neuropathic pain. However, it is also prescribed off-label for a range of other conditions, including anxiety disorders and insomnia.
According to a report, gabapentin ranks sixth in prescribed medication in the United States in 2020. Nearly, 57 million prescriptions were written for the drug in the country in 2020. The report also notes that gabapentin was the country's second-leading prescribed medication for neuropathic pain after pregabalin.
The market in the United States is dominated by generic versions of the drug, which are widely available and often prescribed due to their lower cost. However, branded versions of gabapentin, such as Neurontin, continue to hold a significant market share, particularly for certain indications.
The gabapentin market in the United States is expected to grow in the coming years. Due to the aging population, increasing prevalence of neuropathic pain conditions, and a growing awareness of the drug's efficacy in treating.
The gabapentin market in the United Kingdom is also significant, with the drug being widely prescribed for treating epilepsy and neuropathic pain. Gabapentin is available in various formulations, including capsules, tablets, and oral solutions.
According to a report by the United Kingdom National Health Service, gabapentin was the fourth commonly prescribed medication in 2020. The report also notes that gabapentin was the country's highly prescribed medication for neuropathic pain.
The market in the United Kingdom is dominated by generic versions of the drug, which are widely available and often prescribed due to their lower cost. The branded versions of gabapentin, such as Neurontin, also hold a significant market share.
The United Kingdom has faced increased scrutiny due to concerns about the drug's potential for abuse and addiction. In 2019, gabapentin and pregabalin were reclassified as Class C controlled substances. They are subject to more stringent prescribing and dispensing requirements to reduce the risk of diversion and misuse.
Japan gabapentin market has been growing steadily in recent years, driven by the increasing prevalence of conditions such as epilepsy and neuropathic pain. Additionally, the availability of generic versions of the drug has made it more affordable and accessible for patients.
Regarding market competition, several domestic and international companies offer generic versions of gabapentin in Japan. These companies include Towa Pharmaceutical Co. Ltd., Nippon Chemiphar Co. Ltd., and Teva Pharmaceutical Industries Ltd. The branded gabapentin, Neurontin, is also available in Japan through Pfizer Japan Inc.
In recent years, the market in Japan has faced challenges related to concerns about the drug's potential for abuse and addiction. It has led to stricter regulations for the prescribing and dispensing of gabapentin and other similar drugs, potentially impacting the market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The gabapentin market is highly competitive, with many pharmaceutical companies manufacturing and marketing the drug. The market is dominated by generic versions of the drug, which are widely available and often prescribed due to their lower cost. However, branded versions of gabapentin, such as Neurontin, also hold a significant market share.
The key players in the market include Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., and Mylan N.V. These companies have a strong presence in the market and offer a range of gabapentin formulations and dosages.
These established players and several emerging pharmaceutical companies are also entering the market, driven by the growing demand for the drug. The companies focus on developing novel formulations and delivery methods for gabapentin, improving patient outcomes, and expanding the market.
Other Essential Players in the Market are:
Recent Developments in the Market are:
Several key companies, including Pfizer, Teva Pharmaceutical Industries, Mylan, and Hikma Pharmaceuticals are dominating the global market. Here are some recent developments from these companies in the global market:
Pfizer: Pfizer is one of the leading companies in the market. In 2020, Pfizer settled a lawsuit with the state of Oregon for USD 975,000 over allegations that it engaged in anticompetitive practices to maintain a monopoly over gabapentin. In addition, Pfizer is currently developing a new formulation of gabapentin called PD-217,014, which is being studied for the treatment of neuropathic pain.
Teva Pharmaceutical Industries: Teva is another prominent player in the market. In 2021, Teva announced the launch of a generic version of gabapentin in the United States.
Mylan: Mylan is a global pharmaceutical company that produces a range of medications, including gabapentin. In 2020, Mylan announced the launch of a generic version of gabapentin in the United States
Hikma Pharmaceuticals: Hikma is a multinational pharmaceutical company that produces a range of medications, including gabapentin. In 2020, Hikma announced the launch of a generic version of gabapentin in the United States. The company is also developing a new formulation of gabapentin called HPN-328, which is being studied for treating neuropathic pain.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Market Analysis | USD billion for Value |
| Key Regions Covered | North America; Latin America; The Middle East and Africa; Europe; and Asia Pacific |
| Key Segments Covered | Dosage Form, Type, Region |
| Key Companies Profiled | Pfizer Inc.; Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd.; Aurobindo Pharma Ltd.; Mylan N.V.; Hikma Pharmaceuticals PLC; Zydus Cadila Healthcare Ltd.; Dr. Reddy's Laboratories Ltd.; Lupin Ltd.; Glenmark Pharmaceuticals Ltd.; Apotex Inc.; Amneal Pharmaceuticals Inc.; Torrent Pharmaceuticals Ltd.; Jubilant Life Sciences Ltd.; Cipla Ltd. |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The Gabapentin market is valued at USD 2.11 billion in 2023.
Some of the key players in the Gabapentin market include Pfizer, Sun Pharmaceutical Industries, Mylan, and Teva Pharmaceutical Industries.
Capsules are likely to remain preferred through 2033.
Players opt for product launches and partnerships.
India, Japan, and China dominate the Asian market.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Dosage Form 5.1. Tablet 5.2. Capsule 5.3. Oral Solution 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type 6.1. Generic 6.2. Branded 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application 7.1. Epilepsy 7.2. Neuropathic Pain 7.3. Restless Legs Syndrome 7.4. Other Applications 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 8.1. Hospital Pharmacy 8.2. Retail Pharmacy 8.3. Online Pharmacy 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 9.1. North America 9.2. Latin America 9.3. Europe 9.4. South Asia 9.5. East Asia 9.6. Oceania 9.7. MEA 10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 17. Key Countries Market Analysis 18. Market Structure Analysis 19. Competition Analysis 19.1. Zydus Pharmaceuticals, Inc. 19.2. Glenmark Pharmaceuticals Limited 19.3. Sun Pharmaceutical Industries Ltd. 19.4. Ascend Laboratories, LLC 19.5. Apotex Inc. 19.6. Teva Pharmaceutical Industries Ltd. 19.7. Aurobindo Pharma 19.8. Amneal Pharmaceuticals LLC. 19.9. Cipla USA, Inc. 19.10. BP Pharmaceuticals Laboratories Company 19.11. Assertio Holdings, Inc. 19.12. Arbor Pharmaceuticals, Inc. 19.13. Pfizer Inc. 20. Assumptions & Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Gabapentin Market
